JAMES LEE to Warfarin
This is a "connection" page, showing publications JAMES LEE has written about Warfarin.
Connection Strength
2.121
-
Effect of CYP2C9 *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response. Pharmacogenomics. 2020 12; 21(18):1271-1277.
Score: 0.607
-
Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement. Pharmacogenomics. 2017 Jul; 18(11):1051-1057.
Score: 0.480
-
Clinical and Financial Outcomes Evaluation of Multimodal Pharmacist Warfarin Management of a Statewide Urban and Rural Population. J Pharm Pract. 2018 Apr; 31(2):150-156.
Score: 0.473
-
Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations. Pharmacogenomics. 2023 04; 24(6):303-314.
Score: 0.180
-
Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. Pharmacogenomics. 2022 01; 23(2):85-95.
Score: 0.164
-
Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review. Ann Pharmacother. 2017 Dec; 51(12):1122-1137.
Score: 0.120
-
Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Med Genomics. 2014; 7 Suppl 1:S13.
Score: 0.096